Paris, France-based MedTech startup on a mission to relieve the burden of chronic kidney disease (CKD) on patients and healthcare systems worldwide, Metyos raised EUR 2.3 million in pre-seed funding. The round took place on March 25, 2024. Cenitz led the financing for the company. Meanwhile, KIMA Ventures, Advans Lab, and Bpifrance alongside doctors, leading health insurance angels, and business leaders from Implicity, Deepmind and Nabla also joined in the fundraise.
Purpose of financing for the company
With the latest financing, Metyos seeks to develop its wearable technology further, including progressing it through clinical trials ahead of FDA clearance.
What the company’s official has to add
Alexandre Boulanger, CEO and Co-founder of Metyos said, “Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management. A healthcare future where millions of CKD patients are empowered to take control of their health and where they can access life-saving early detection and personalised interventions. This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”
What the investors have to comment
Frederic Picq at Cenitz added, “Our investment in Metyos was driven by its impressive founding team, a clear and growing market need, and the life-changing potential of its technology. Alex and Olga bring a blend of entrepreneurial spirit and technical expertise that is rare and invaluable in the medtech space. Their track record and passion for healthcare innovation are evident in the strides Metyos has already made. We see significant opportunity in Metyos not just because of its groundbreaking approach to CKD management but because it represents the future of healthcare – a future where technology and the human experience come together to offer better, proactive care for all.”
About the company
Alexandre Boulanger and Olga Chashchina are the founders of the company launched in 2011.
At the Healthcare Innovation World Cup, Metyos’ team was recognized as one of the leading global health techpreneurs, and the company has already won the Embedded Healthcare Trophy at the Association Embedded France awards.
Metyos aims to enhance the quality of life, results, and expenses related to the management of chronic kidney disease (CKD), which impacts 10% of the global population and is the third leading cause of death. Doctors may monitor a patient’s kidney function in real-time by using real-time readings of biomarkers linked to chronic kidney disease (CKD) with Metyos’ biowearable sensor and platform.
Metyos’ goal is to assist both parties in proactively managing symptoms in order to limit the spread of this expensive and incapacitating illness.
To explore more such startups, visit Zefyron Startup Database
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 on patients and healthcare systems worldwide, Metyos raised EUR 2.3 million in pre-seed funding){kind=link}